Federated Hermes’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $903 | Buy |
+398
| New | +$903 | ﹤0.01% | 2008 |
|
|
2024
Q4 | – | Sell |
-117
| Closed | -$138 | – | 2100 |
|
|
2024
Q3 | $138 | Hold |
117
| – | – | ﹤0.01% | 2019 |
|
|
2024
Q2 | $143 | Sell |
117
-4,271
| -97% | -$5.22K | ﹤0.01% | 1990 |
|
|
2024
Q1 | $9.57K | Buy |
4,388
+903
| +26% | +$1.97K | ﹤0.01% | 1780 |
|
|
2023
Q4 | $5.4K | Buy |
3,485
+2,070
| +146% | +$3.21K | ﹤0.01% | 1843 |
|
|
2023
Q3 | $1.83K | Hold |
1,415
| – | – | ﹤0.01% | 1975 |
|
|
2023
Q2 | $2.43K | Hold |
1,415
| – | – | ﹤0.01% | 1983 |
|
|
2023
Q1 | $2.14K | Sell |
1,415
-2,127
| -60% | -$3.21K | ﹤0.01% | 1999 |
|
|
2022
Q4 | $5.67K | Sell |
3,542
-715
| -17% | -$1.14K | ﹤0.01% | 1915 |
|
|
2022
Q3 | $6K | Buy |
4,257
+424
| +11% | +$598 | ﹤0.01% | 1873 |
|
|
2022
Q2 | $7K | Buy |
3,833
+3,752
| +4,632% | +$6.85K | ﹤0.01% | 1858 |
|
|
2022
Q1 | $1K | Sell |
81
-961,393
| -100% | -$11.9M | ﹤0.01% | 2076 |
|
|
2021
Q4 | $4.16M | Sell |
961,474
-123
| -0% | -$533 | 0.01% | 864 |
|
|
2021
Q3 | $4.9M | Buy |
961,597
+29,590
| +3% | +$151K | 0.01% | 830 |
|
|
2021
Q2 | $5.9M | Buy |
932,007
+338,586
| +57% | +$2.14M | 0.01% | 795 |
|
|
2021
Q1 | $4.59M | Buy |
593,421
+230,763
| +64% | +$1.78M | 0.01% | 880 |
|
|
2020
Q4 | $2.38M | Buy |
362,658
+344,186
| +1,863% | +$2.25M | ﹤0.01% | 999 |
|
|
2020
Q3 | $123K | Buy |
18,472
+11,653
| +171% | +$77.6K | ﹤0.01% | 1709 |
|
|
2020
Q2 | $57K | Buy |
+6,819
| New | +$57K | ﹤0.01% | 1763 |
|
|
2019
Q4 | – | Sell |
-6,970
| Closed | -$51K | – | 2224 |
|
|
2019
Q3 | $51K | Buy |
+6,970
| New | +$51K | ﹤0.01% | 1721 |
|
|
2018
Q2 | – | Sell |
-125,932
| Closed | -$3.58M | – | 2208 |
|
|
2018
Q1 | $3.58M | Buy |
125,932
+56,582
| +82% | +$1.61M | 0.01% | 740 |
|
|
2017
Q4 | $1.46M | Buy |
+69,350
| New | +$1.46M | ﹤0.01% | 1066 |
|